ZEN003365 / Zenith Capital Corp - LARVOL DELTA

The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia. (PubMed, Ann Hematol) - "We show that ZEN-3365 alone or in combination with GANT-61 reduced GLI promoter activity, cell proliferation and colony formation in AML cell lines and primary cells. Our findings strongly support the evaluation of the BRD4 inhibitor ZEN-3365 as a new therapeutic option in AML."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • BRD4

Zenith Epigenetics update (Canada Newswire) - "Zenith Epigenetics ...is suspending its clinical development efforts with ZEN-3365...decision is unrelated to the preclinical safety and efficacy attributes of ZEN-3365. The company will continue to aggressively advance preclinical development activities with another differentiated proprietary small molecule BET inhibitor and is targeting the second half of 2015 to initiate Phase 1 clinical trials in oncology."

Discontinued • Acute Myelogenous Leukemia • Oncology